with the proviso that at most two of X^1, X^2, X^3, X^4 denote N, and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1 in which

R^1 denotes H, F, Cl, Br, CN, CH_3, CF_3 or OCH_3,

R^2 denotes H or F,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 or 2, in which

R^3 denotes phenyl, pyridyl, pyrimidinyl, indolyl, indazolyl, thiophenyl, dihydroisoindolyl or benzimidazolyl, each of which is un-substituted or mono-, di- or tri-substituted by Hal, A, $(CR^4)_nOR^4$, $(CR^4)_nN(R^4)_2$, $(CR^4)_nS(O)_mR^4$, $(CR^4)_nCON(R^4)_2$, $(CR^4)_nCOHet$, $(CR^4)_nSO_2$-Het, $(CR^4)_nHet$, $O(CR^4)_nCOHet$, $(CR^4)_nO(CR^4)_nHet$, $(CR^4)_nN(R^4)(CR^4)_n$ Het, $(CR^4)_n$ CO-$N(R^4)(CR^4)_nHet$, $(CR^4)_nCON(R^4)$ $(CR^4)_nN(R^4)_2$, $(CR^4)_nN(R^4)COA$, $(CR^4)_nN(R^4)COHet'$, $(CR^4)_nOCyc$ and/or $(CR^4)_nCOOR^4$,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to one or more of Claims 1-3, in which

A denotes unbranched or branched alkyl with 1-10 C-atoms, wherein two adjacent carbon atoms may form a double bond and/or one or two non-adjacent CH- and/or CH_2-groups may be replaced by N- and/or O-atoms and wherein 1-7 H-atoms may be replaced by R^5,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

5. Compounds according to one or more of Claims 1-4, in which

Het' denotes pyrrolidinyl,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

6. Compounds according to one or more of Claims 1-5, in which

X^1, X^2, X^3, X^4 each, independently of one another, denote CH or N,

Y denotes N or CH,

Q denotes H or CH_3,

R^1 denotes H, F, Cl, Br, CN, CH_3, CF_3 or OCH_3,

R^2 denotes H or F,

R^3 denotes phenyl, pyridyl, pyrimidinyl, indolyl, indazolyl, thiophenyl, dihydroisoindolyl or benzimidazolyl, each of which is un-substituted or mono-, di- or tri-substituted by Hal, A, $(CR^4)_nOR^4$, $(CR^4)_nN(R^4)_2$, $(CR^4)_nS(O)_mR^4$, $(CR^4)_nCON(R^4)_2$, $(CR^4)_n$ COHet, $(CR^4)_nSO_2$ Het, $(CR^4)_n$Het, $O(CR^4)_n$COHet, $(CR^4)_nO(CR^4)_n$Het, $(CR^4)_nN(R^4)$ $(CR^4)_n$ Het, $(CR^4)_n$CON $(R^4)(CR^4)_n$Het, $(CR^4)_nCON(R^4)(CR^4)_nN(R^4)_2$, $(CR^4)_nN$ (R^4)COA, $(CR^4)_nN(R^4)$CO Het', $(CR^4)_n$OCyc and/or $(CR^4)_n$COOR^4,

R^4 denotes H or A',

A denotes unbranched or branched alkyl with 1-10 C-atoms, wherein two adjacent carbon atoms may form a double bond and/or one or two non-adjacent CH- and/or CH_2-groups may be replaced by N- and/or O-atoms and wherein 1-7 H-atoms may be replaced by R^5,

Cyc denotes cyclobutyl, cyclopentyl or cyclohexyl, each of which is un-substituted or mono- or di-substituted by A, Hal, OR^4, $N(R^4)_2$, Het', $(CR^4)_nO(CR^4)_n$Het', $CON(R^4)_2$ and/or =O,

A' denotes unbranched or branched alkyl with 1-6 C-atoms, wherein one or two non-adjacent CH- and/or CH_2-groups may be replaced by O-atoms,

R^5 denotes F, Cl or OH,

Het denotes pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, [1,4]-diazepanyl, oxazolidin-yl, hexahydropyrrolo[3,4-c]pyrrolyl, 2-oxa-6-azaspiro[3.4]octanyl, 2-oxa-6-azaspiro[3.5]-nonanyl, 2-oxa-7-azaspiro[3.5]nonanyl, 2,5-dioxa-8-azaspiro[3.5]nonanyl, oxetan- yl, 2-oxa-5-azaspiro[3.4]octanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 3-azabicycle[3.1.0]hexanyl, 2-oxa-7-azaspiro[3.5]nonanyl, isoxazolidinyl, azetidinyl, 2,6-diazaspiro[3.4]octanyl, hexa hydropyrrolo[3, 4-b]pyrrolyl, tetrahydrofuranyl or iso-thiazolidinyl, each of which is un substituted or mono-, di- or tri-substituted by A, Hal, OR^4, OCOA, COA, $(CR^4)_nN(R^4)_2$, $(CR^4)_n$Het', $(CR^4)_nO(CR^4)_n$Het', $CON(R^4)_2$, COHet', $(CR^4)_nS(O)_mR^4$, and/or =O,

Het' denotes pyrrolidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyridyl or pyrazolyl,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2 or 3,

m denotes 0, 1 or 2,

with the proviso that at most two of X^1, X^2, X^3, X^4 denote N, and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

7. Compounds according to Claim 1, selected from the group

No.	Name
"A1"	6-fluoro-3-{1-[4-(morpholine-4-carbonyl)-phenyl]-1H-[1,2,3]triazol-4-yl}-1H-quinolin-2-one